PureTech Health plc (LON:PRTC)
142.00
-4.00 (-2.74%)
Feb 21, 2025, 4:35 PM BST
PureTech Health Employees
PureTech Health had 90 employees as of December 31, 2023. The number of employees decreased by 21 or -18.92% compared to the previous year.
Employees
90
Change (1Y)
-21
Growth (1Y)
-18.92%
Revenue / Employee
4.11K GBP
Profits / Employee
-725.03K GBP
Market Cap
339.98M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 89,900 |
GSK plc | 70,212 |
Haleon | 25,408 |
Smith & Nephew | 18,452 |
Hikma Pharmaceuticals | 9,100 |
ConvaTec Group | 10,136 |
HUTCHMED (China) | 1,988 |
Genus | 3,500 |
PureTech Health News
- 10 days ago - CITIGROUP INC Acquires 10,703,044 Shares in PureTech Health PLC - GuruFocus
- 11 days ago - PureTech Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Platform - Business Wire
- 27 days ago - PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine - Business Wire
- 6 weeks ago - Zentalis Pharmaceuticals and PureTech Health get Fast Track Designation from FDA for their cancer treatments - Seeking Alpha
- 6 weeks ago - PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML) - Business Wire
- 6 weeks ago - PureTech Appoints UBS as UK Corporate Broker - Business Wire
- 2 months ago - Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket - Benzinga
- 2 months ago - PureTech's Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial - Business Wire